NEW YORK (GenomeWeb) – UK-based diagnostics firm Oncimmune said today that it has signed an agreement with US clinical laboratory Accu Reference for the firm to offer Oncimmune's EarlyCDT-Lung test to physicians.

The EarlyCDT-Lung test measures levels of seven autoantibodies in patient blood to aid in the early detection of lung cancer. Oncimmune markets the test both for detecting lung cancer before it can be picked up via imaging techniques like CT scans and for helping to evaluate whether nodules detected via imaging are likely malignant or benign.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.